2 research outputs found

    Age-related selection bias in Parkinson's disease research : are we recruiting the right participants?

    Get PDF
    Acknowledgements We acknowledge the earlier work of Dr Kate Taylor and Dr Dominique Twelves on the previous systematic review of incidence studies in Parkinsonā€™s disease. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Authors report the following funding received during the conduct of this study: Dr Macleod: fellowship funding from the Chief Scientist Office of the Scottish Government and NHS Education for Scotland; grant funding Parkinsonā€™s UK, the Academy of Medical Sciences, NHS Grampian Endowments, the Wellcome Trust, the University of Aberdeen. Dr Henery: financial support from the University of Aberdeen Dr Nwajiugo: none Dr Scott: none Dr Caslake: grant funding from Parkinsonā€™s UK Dr Counsell: grant funding from the Chief Scientist Office of the Scottish Government, the PSP Association, and NHS Grampian Endowments.Peer reviewedPostprin

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; pā€‰=ā€‰0.40). There was no significant effect of DMF on any secondary outcome
    corecore